Quantitative autoradiographic localization in rat brain of α 2-adrenergic and non-adrenergic I-receptor binding sites labelled by [3H]rilmenidine

alpha 2A-Adrenergic receptor (AR) and non-adrenergic imidazoline receptor (I-R) binding sites have been previously characterized in rat cerebral cortex membranes using the N-substituted oxazoline, [3H]rilmenidine ([3H]Ril) [King, P.R. et al., Eur. J. Pharmacol., 218 (1992) 101-108]. In the present study, in vitro autoradiography was used to quantify the regional distribution of these receptors throughout the rat neuroaxis. The distribution and relative density (fmol/mg tissue) of I-Rs was examined in the presence of 1 microM adrenaline to block the adrenergic component of 40 nM [3H]Ril binding and non-specific binding was measured in the presence of another oxazoline, Bay a6781 (10 microM). Both alpha 2A-ARs and I-Rs were broadly, but heterogeneously, distributed. In forebrain, high levels of [3H]Ril-labelled alpha 2A-AR sites were observed in the anterior olfactory nucleus, the piriform, entorhinal and perirhinal cortices, lateral septum, bed nucleus of the stria terminalis, several thalamic nuclei, the amygdala and the arcuate, dorsomedial and posterior hypothalamic nuclei. In hindbrain, alpha 2A-AR sites were concentrated in locus coeruleus, lateral parabrachial nucleus, nucleus of the solitary tract and area postrema. I-R sites accounted for 50% or more of specific [3H]Ril binding (40 nM) in most cortical and hypothalamic nuclei, nucleus of the solitary tract, cranial motor nuclei and most spinal cord layers. The highest densities of I-Rs were found in the arcuate, dorsomedial and posterior hypothalamic nuclei, the locus coeruleus, the area postrema, the cranial motor nuclei and associated with spinal motor neurones. A very high concentration of I-Rs was also detected in the pineal gland. The distribution of alpha 2-AR sites determined resembled that reported with [3H]p-aminoclonidine which appears to specifically label alpha 2-ARs and not I1-R sites in rat brain sections, and [3H]methoxyidazoxan which is a selective alpha 2-AR antagonist. The regional and cellular distribution of I-R binding sites was unlike the distribution of putative I1-R sites labelled by [3H]clonidine in human brain, although comparable autoradiographic mapping studies in rat brain have not been done using this ligand. The regional and cellular distribution of [3H]-labelled I-R binding sites had both similarities and differences to that reported using the imidazoline ligand, [3H]idazoxan, with common labelling of areas such as area postrema, arcuate and interpeduncular nuclei and pineal gland with the two ligands, and differential relative binding levels ([3H]Ril > [3H]idazoxan) associated with hippocampal pyramidal cells and brainstem and spinal motor neurones.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  K. Starke,et al.  Is the sympathoinhibitory effect of rilmenidine mediated by alpha-2 adrenoceptors or imidazoline receptors? , 1994, The Journal of pharmacology and experimental therapeutics.

[2]  J. Wikberg High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: description of a putative idazoxan-receptor. , 1989, Pharmacology & toxicology.

[3]  P. R. King,et al.  Molecular studies of alpha‐2‐adrenoceptor and catecholamine‐insensitive imidazoline‐receptor binding sites using [3H]-rilmenidine in rat brain and kidney , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[4]  F. Leslie,et al.  Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[5]  D. Reis,et al.  Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. , 1990, The Journal of pharmacology and experimental therapeutics.

[6]  M. Dontenwill,et al.  The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. , 1989, European journal of pharmacology.

[7]  J. De Keyser,et al.  High affinity binding of 3H rauwolscine and 3H RX781094 to alpha 2 adrenergic receptors and non-stereoselective sites in human and rabbit brain cortex membranes. , 1989, Biochemical pharmacology.

[8]  A. Hudson,et al.  Characterization and autoradiographical localization of non‐adrenoceptor idazoxan binding sites in the rat brain , 1992, British journal of pharmacology.

[9]  M. Wood,et al.  Heterogeneous 3H-rauwolscine binding sites in rat cortex: two alpha 2-adrenoceptor subtypes or an additional non-adrenergic interaction? , 1988, Life sciences.

[10]  U. Schambra,et al.  Distribution of α2-adrenergic receptor subtype gene expression in rat brain , 1994 .

[11]  T. Ishikawa,et al.  Binding of [3H]p-aminoclonidine to two sites, α2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain , 1990, Brain Research.

[12]  G. Brüning,et al.  Quantitative autoradiographic localization of α 2-antagonist binding sites in rat brain using [3H]idazoxan , 1987, Neuroscience Letters.

[13]  J. Wikberg,et al.  Further Characterization of the Guinea Pig Cerebral Cortex Idazoxan Receptor: Solubilization, Distinction from the Imidazole Site, and Demonstration of Cirazoline as an Idazoxan Receptor‐Selective Drug , 1990, Journal of neurochemistry.

[14]  P. R. King,et al.  Nature of [3H]rilmenidine binding to membranes of rat cerebral cortex. , 1992, American journal of hypertension.

[15]  O. Lindvall,et al.  The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method. , 1974, Acta physiologica Scandinavica. Supplementum.

[16]  J. Schwartz,et al.  Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. , 1984, The Journal of pharmacology and experimental therapeutics.

[17]  H. Jackson,et al.  The effects of idazoxan and other α2‐adrenoceptor antagonists on food and water intake in the rat , 1991, British journal of pharmacology.

[18]  M. Dontenwill,et al.  Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit , 1990, British journal of pharmacology.

[19]  F. Gonon,et al.  Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors. , 1991, European journal of pharmacology.

[20]  C. Martin,et al.  Keeping an eye on the I site: imidazoline-prefemng receptors , 1992 .

[21]  M. Spedding,et al.  α2‐Adrenoceptor subtypes and imidazoline‐like binding sites in the rat brain , 1990 .

[22]  D. Reis,et al.  Hypotensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha‐2-adrenergic receptors in the rostral ventrolateral medulla , 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[23]  J. Leysen,et al.  Optimal Conditions for [3H]Apomorphine Binding and Anomalous Equilibrium Binding of [3H]Apomorphine and [3H]Spiperone to Rat Striatal Membranes: Involvement of Surface Phenomena Versus Multiple Binding Sites , 1981, Journal of neurochemistry.

[24]  J. Saura,et al.  Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  J. Palacios,et al.  Distribution of α2-adrenergic receptors in the human brainstem: An autoradiographic study using [3H]p-aminoclonidine , 1984 .

[26]  A. Miralles,et al.  Characterization of brain imidazoline receptors in normotensive and hypertensive rats: differential regulation by chronic imidazoline drug treatment. , 1992, The Journal of pharmacology and experimental therapeutics.

[27]  D. Reis,et al.  Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla. , 1987, European journal of pharmacology.

[28]  P. Timmermans,et al.  Central and peripheral effects of S 3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models. , 1986, Archives internationales de pharmacodynamie et de therapie.

[29]  J. Reid,et al.  [3H]yohimbine and [3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. , 1988, European journal of pharmacology.

[30]  H. Lal,et al.  Psychopharmacology of clonidine , 1981 .

[31]  P. Escribá,et al.  Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down‐regulates non‐adrenoceptor [3H]‐idazoxan binding sites in the rat brain , 1993, British journal of pharmacology.

[32]  G. Vauquelin,et al.  [3H]Rauwolscine labels α2-adrenoceptors and 5-HT1A receptors in human cerebral cortex , 1989 .

[33]  J. Pujol,et al.  Distribution of alpha-1 and alpha-2 binding sites in the rat locus coeruleus , 1991, Brain Research Bulletin.

[34]  P. Ernsberger,et al.  Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. , 1993, The Journal of pharmacology and experimental therapeutics.

[35]  P. Insel,et al.  Are there multiple imidazoline binding sites? , 1989, Trends in pharmacological sciences.

[36]  Jaak Panksepp,et al.  Handbook of the hypothalamus , 1979 .

[37]  D. Reis,et al.  Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. , 1991, European journal of pharmacology.

[38]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[39]  J. Hieble,et al.  L 1 ‐ IMIDAZOLINE RECEPTORS: HISTORICAL PERSPECTIVE , 1992 .

[40]  M. Dontenwill,et al.  Rilmenidine selectivity for imidazoline receptors in human brain. , 1989, European journal of pharmacology.

[41]  G. Vauquelin,et al.  Autoradiographic distribution of α 2 adrenoceptors, NAIBS, and 5-HT1A receptors in human brain using [3H]idazoxan and [3H]rauwolscine , 1991, Brain Research.

[42]  J. Feldman,et al.  The blood pressure effects of alpha-adrenoceptor antagonists injected in the medullary site of action of clonidine: the nucleus reticularis lateralis. , 1987, Life sciences.

[43]  M. Wyllie,et al.  A reassessment of the binding of [3H]rauwolscine to membranes from the rat cortex , 1986, Neuropharmacology.

[44]  A. Miralles,et al.  Repeated Idazoxan Increases Brain Imidazoline Receptors in Normotensive (WKY) but Not in Hypertensive (SHR) Rats , 1991, Journal of neurochemistry.

[45]  P. R. King,et al.  α2-adrenoceptor and catecholamine-insensitive binding sites for [3H]rilmenidine in membranes from rat cerebral cortex , 1992 .

[46]  F. Leslie,et al.  Further pharmacological characterization of [3H]idazoxan binding sites in rat brain: evidence for predominant labeling ofα 2-adrenergic receptors , 1992, Brain Research.

[47]  G. Bricca,et al.  Heterogeneity of the specific imidazoline binding of [3H]idazoxan in the human cerebral cortex , 1993, Neurochemistry International.

[48]  M. Dontenwill,et al.  Relevance of the use of [3H]‐clonidine to identify imidazoline receptors in the rabbit brainstem , 1993, British journal of pharmacology.

[49]  S. Loughlin,et al.  Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[50]  G. Vauquelin,et al.  Imidazoline receptors, non-adrenergic idazoxan binding sites and α2-adrenoceptors in the human central nervous system , 1994, Neuroscience.

[51]  A. Miralles,et al.  Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. , 1993, The Journal of pharmacology and experimental therapeutics.

[52]  R. Stornetta,et al.  Immunohistochemical localization ofα2a-adrenergic receptors in catecholaminergic and other brainstem neurons in the rat , 1993, Neuroscience.

[53]  F E Bloom,et al.  Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. , 1979, Annual review of neuroscience.

[54]  D. Bylund,et al.  α 2-agonist binding sites in brain: [125I]Para-iodoclonidine versus [3H]para-aminoclonidine , 1993, Brain Research Bulletin.

[55]  P. Widdowson,et al.  [3H]‐idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2‐type receptors: pharmacological characterization and relationship to monoamine oxidase , 1993, British journal of pharmacology.

[56]  F. Tesson,et al.  L 5 ‐ IMIDAZOLINE‐GUANIDINIUM RECEPTIVE SITE (IGRS): MITOCHONDRIAL DISTRIBUTION AND REGULATION PROPERTIES , 1992, Fundamental & clinical pharmacology.

[57]  D. Reis,et al.  Reduction in Focal Cerebral Ischemia by Agents Acting at Imidazole Receptors , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[58]  D. Reis,et al.  L 3 ‐ IMIDAZOLINE RECEPTORS IN THE NERVOUS SYSTEM , 1992, Fundamental & clinical pharmacology.

[59]  M. Sastre,et al.  Opposite Age‐Dependent Changes of α2A‐Adrenoceptors and Nonadrenoceptor [3H]Idazoxan Binding Sites (I2‐Imidazoline Sites) in the Human Brain: Strong Correlation of I2 with Monoamine Oxidase‐B Sites , 1993, Journal of neurochemistry.

[60]  A. Steffens,et al.  University of Groningen The Hypothalamus, Intrinsic Connections and Outflow Pathways to the Endocrine System in Relation to the Control of Feeding and Metabolism Luiten, , 2002 .

[61]  M. Kuhar,et al.  Distribution of α2 agonist binding sites in the rat and human central nervous system: Analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents , 1984, Brain Research Reviews.

[62]  M. Dontenwill,et al.  Human brain imidazoline receptors: further characterization with [3H]clonidine. , 1994, European journal of pharmacology.

[63]  K. Fuxe,et al.  EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM. , 1965, Acta physiologica Scandinavica. Supplementum.